Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China.
Future Oncol. 2021 Jul;17(19):2489-2498. doi: 10.2217/fon-2020-0992. Epub 2021 Apr 28.
The aim of this study was to analyze the correlations between NAT1 and clinicopathological features of and prognosis in colorectal cancer (CRC). RNA sequencing data and clinical information were retrieved from The Cancer Genome Atlas database. Wilcoxon test, logistic regression and Kaplan-Meier method were used to estimate the association between NAT1 and prognosis in CRC. experiments were conducted to confirm the role of NAT1. is significantly less expressed in CRC and independently associated with poor prognosis in CRC patients. The authors further confirmed that expression of was significantly lower in SW116 colon cancer cells than in NCM460 cells. Overexpressed obviously inhibited the growth of CRC cells by downregulating phosphorylation of the PI3K/Akt/mTOR signaling pathway. NAT1 may be a potential therapeutic target for CRC.
本研究旨在分析 NAT1 与结直肠癌（CRC）的临床病理特征和预后之间的相关性。从癌症基因组图谱（TCGA）数据库中提取 RNA 测序数据和临床信息。采用 Wilcoxon 检验、逻辑回归和 Kaplan-Meier 法评估 NAT1 与 CRC 预后之间的相关性。进行实验以验证 NAT1 的作用。结果表明，在 CRC 中表达明显降低，与 CRC 患者的不良预后独立相关。作者进一步证实，与 NCM460 细胞相比，SW116 结肠癌细胞中 的表达明显降低。过表达 可通过下调 PI3K/Akt/mTOR 信号通路的磷酸化明显抑制 CRC 细胞的生长。NAT1 可能是 CRC 的潜在治疗靶点。
